Drug Trial Radar · NCT07697586
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
206
Planned (sponsor's estimate)
Start
Aug 7, 2026
Primary completion
Aug 2028
Study completion Aug 2029
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC. The study includes a dose escalation phase and an expansion phase.
Conditions
- NSCLC
Interventions
SKB264+SKB118Drug
Administered by intravenous infusion on Day 1 and Day 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: From enrollment to the end of treatment at 24 months
- ORR(objective response rate)Time frame: From enrollment to the end of treatment at 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jilin Cancer Hospital
Jilin City, China · Not yet recruiting
Shanghai East Hospital, Tongji University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.